Works matching IS 14783223 AND DT 2019 AND VI 39 AND IP 12
Results: 26
How effective and how durable is DAA‐therapy in HCV‐infected drug users?
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2238, doi. 10.1111/liv.14284
- By:
- Publication type:
- Article
Issue Cover.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. i, doi. 10.1111/liv.14277
- By:
- Publication type:
- Article
Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular‐cholangiocarcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2386, doi. 10.1111/liv.14261
- By:
- Publication type:
- Article
Surgical resection versus radiofrequency ablation very early‐stage HCC (≤2 cm Single HCC): A propensity score analysis.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2397, doi. 10.1111/liv.14258
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2408, doi. 10.1111/liv.14257
- By:
- Publication type:
- Article
Abstracts.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2420, doi. 10.1111/liv.14255
- By:
- Publication type:
- Article
Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study).
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2240, doi. 10.1111/liv.14242
- By:
- Publication type:
- Article
The ATG16L1 gene variant rs2241880 (p.T300A) is associated with susceptibility to HCC in patients with cirrhosis.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2360, doi. 10.1111/liv.14239
- By:
- Publication type:
- Article
The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2261, doi. 10.1111/liv.14227
- By:
- Publication type:
- Article
Plasma N‐terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non‐alcoholic fatty liver disease.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2317, doi. 10.1111/liv.14225
- By:
- Publication type:
- Article
Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2341, doi. 10.1111/liv.14224
- By:
- Publication type:
- Article
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2214, doi. 10.1111/liv.14223
- By:
- Publication type:
- Article
Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case‐control study.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2291, doi. 10.1111/liv.14221
- By:
- Publication type:
- Article
The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2374, doi. 10.1111/liv.14217
- By:
- Publication type:
- Article
Changes in alpha‐foetoprotein and Gc‐globulin in relation to outcomes in non‐acetaminophen acute liver failure.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2368, doi. 10.1111/liv.14216
- By:
- Publication type:
- Article
HBV‐Pol is crucial for HBV‐mediated inhibition of inflammasome activation and IL‐1β production.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2273, doi. 10.1111/liv.14214
- By:
- Publication type:
- Article
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2309, doi. 10.1111/liv.14213
- By:
- Publication type:
- Article
microRNA‐206 modulates the hepatic expression of the organic anion‐transporting polypeptide 1B1.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2350, doi. 10.1111/liv.14212
- By:
- Publication type:
- Article
France removes hepatitis C treatment prescriber restrictions—But what is the impact of the delay for key populations?
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2418, doi. 10.1111/liv.14208
- By:
- Publication type:
- Article
Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non‐alcoholic fatty liver disease.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2301, doi. 10.1111/liv.14206
- By:
- Publication type:
- Article
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2285, doi. 10.1111/liv.14201
- By:
- Publication type:
- Article
Effects of adenovirus‐induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2330, doi. 10.1111/liv.14183
- By:
- Publication type:
- Article
Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2230, doi. 10.1111/liv.14180
- By:
- Publication type:
- Article
Budd‐Chiari syndrome in the West and the East: Same syndrome, different diseases.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2417, doi. 10.1111/liv.14131
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2209, doi. 10.1111/liv.13913
- Publication type:
- Article
Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2244, doi. 10.1111/liv.14152
- By:
- Publication type:
- Article